AAPL   267.01 (-2.38%)
MSFT   158.12 (-0.04%)
AMZN   1,842.20 (-2.23%)
CGC   18.00 (-2.39%)
NVDA   259.48 (+2.72%)
TSLA   636.60 (-6.24%)
F   6.79 (-2.58%)
AAPL   267.01 (-2.38%)
MSFT   158.12 (-0.04%)
AMZN   1,842.20 (-2.23%)
CGC   18.00 (-2.39%)
NVDA   259.48 (+2.72%)
TSLA   636.60 (-6.24%)
F   6.79 (-2.58%)
AAPL   267.01 (-2.38%)
MSFT   158.12 (-0.04%)
AMZN   1,842.20 (-2.23%)
CGC   18.00 (-2.39%)
NVDA   259.48 (+2.72%)
TSLA   636.60 (-6.24%)
F   6.79 (-2.58%)
AAPL   267.01 (-2.38%)
MSFT   158.12 (-0.04%)
AMZN   1,842.20 (-2.23%)
CGC   18.00 (-2.39%)
NVDA   259.48 (+2.72%)
TSLA   636.60 (-6.24%)
F   6.79 (-2.58%)
Log in

OTCMKTS:HKMPF - Hikma Pharmaceuticals Stock Price, Forecast & News

$24.40
0.00 (0.00 %)
(As of 02/28/2020 10:12 AM ET)
Today's Range
$24.40
Now: $24.40
$24.40
50-Day Range
$23.00
MA: $23.89
$25.85
52-Week Range
$20.90
Now: $24.40
$26.65
Volume30 shs
Average Volume91 shs
Market Capitalization$5.88 billion
P/E Ratio17.68
Dividend YieldN/A
Beta0.16
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals. Read More…

Industry, Sector and Symbol

Industry Private households
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:HKMPF
CUSIPN/A
CIKN/A
Phone44-20-7399-2760

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.07 billion
Cash Flow$1.88 per share
Book Value$7.05 per share

Profitability

Miscellaneous

Employees8,464
Market Cap$5.88 billion
Next Earnings Date5/28/2020 (Estimated)
OptionableNot Optionable

Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for HKMPF and its competitors with MarketBeat's FREE daily newsletter.


Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

When is Hikma Pharmaceuticals' next earnings date?

Hikma Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, May 28th 2020. View Earnings Estimates for Hikma Pharmaceuticals.

What is the consensus analysts' recommendation for Hikma Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Hikma Pharmaceuticals.

Has Hikma Pharmaceuticals been receiving favorable news coverage?

Headlines about HKMPF stock have been trending very negative on Friday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Hikma Pharmaceuticals earned a news impact score of -3.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Hikma Pharmaceuticals.

Who are some of Hikma Pharmaceuticals' key competitors?

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include Hikma Pharmaceuticals (HIK), Tilray (TLRY), Myriad Genetics (MYGN), Alibaba Group (BABA), Suncor Energy (SU), ArcBest (ARCB), Avinger (AVGR), Atlantica Yield (AY), Bellerophon Therapeutics (BLPH) and BIOLINERX LTD/S (BLRX).

Who are Hikma Pharmaceuticals' key executives?

Hikma Pharmaceuticals' management team includes the folowing people:
  • Mr. Said Samih Taleb Darwazah, Exec. Chairman (Age 62)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 61)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 50)
  • Mr. Khalid Walid Hussni Nabilsi, Chief Financial Officer (Age 47)
  • Dr. Surendera Tyagi, Group Chief Scientific Officer and Global Head of R&D

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $24.40.

How big of a company is Hikma Pharmaceuticals?

Hikma Pharmaceuticals has a market capitalization of $5.88 billion and generates $2.07 billion in revenue each year. The company earns $282 million in net income (profit) each year or $1.38 on an earnings per share basis. Hikma Pharmaceuticals employs 8,464 workers across the globe.View Additional Information About Hikma Pharmaceuticals.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is http://www.hikma.com/.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]


MarketBeat Community Rating for Hikma Pharmaceuticals (OTCMKTS HKMPF)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  108 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals and other stocks. Vote "Outperform" if you believe HKMPF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HKMPF will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Featured Article: Percentage Gainers

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel